Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology.THOUSAND OAKS Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown. , Calif. -- Amgen (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AMGN) issued the following statement on the publication of an Aranesp([R]) (darbepoetin alfa darbepoetin alfa Aranesp Pharmacologic class: Recombinant human erythropoietin Therapeutic class: Hematopoietic Pregnancy risk category C FDA Boxed Warning) manuscript in the January 28, 2008, online issue of the Journal of Clinical Oncology The Journal of Clinical Oncology is a medical journal published by the American Society of Clinical Oncology. The Journal was founded in 1983 and publishes original research and review articles on topics relating to cancer. It is published 3 times a month. . Amgen anticipates this manuscript will be available in the March 1, 2008, print edition."The '103 Anemia of Cancer' study, a Phase 3 trial designed to test whether anemic anemic pertaining to anemia. patients with active cancer not receiving concurrent chemotherapy or radiotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, communicated to physicians through a 'Dear Healthcare Provider' letter, and presented at a scientific conference and other venues throughout last year. "Amgen is committed to ensuring physicians and their patients have the most up-to-date information on its medicines, including both positive and negative results from clinical trials." |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion